{
    "root": "361ee404-9599-0df9-e063-6294a90a14ae",
    "code": "34391-3",
    "codeSystem": "2.16.840.1.113883.6.1",
    "displayName": "HUMAN PRESCRIPTION DRUG LABEL",
    "name": "Sertraline Hydrochloride",
    "value": "20250527",
    "ingredients": [
        {
            "name": "DIBASIC CALCIUM PHOSPHATE DIHYDRATE",
            "code": "O7TSZ97GEP",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_77635"
        },
        {
            "name": "HYDROXYPROPYL CELLULOSE, UNSPECIFIED",
            "code": "9XZ8H6N6OH",
            "drugbank_id": "https://go.drugbank.com/drugs/DB00840"
        },
        {
            "name": "MICROCRYSTALLINE CELLULOSE",
            "code": "OP1R32D61U",
            "drugbank_id": "https://go.drugbank.com/drugs/DB14158"
        },
        {
            "name": "MAGNESIUM STEARATE",
            "code": "70097M6I30",
            "drugbank_id": "https://go.drugbank.com/drugs/DB14077"
        },
        {
            "name": "SODIUM STARCH GLYCOLATE TYPE A POTATO",
            "code": "5856J3G2A2",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_28017"
        },
        {
            "name": "TITANIUM DIOXIDE",
            "code": "15FIX9V2JP",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_32234"
        },
        {
            "name": "HYPROMELLOSE 2910 (3 MPA.S)",
            "code": "0VUT3PMY82",
            "drugbank_id": "https://go.drugbank.com/drugs/DB11075"
        },
        {
            "name": "HYPROMELLOSE 2910 (6 MPA.S)",
            "code": "0WZ8WG20P6",
            "drugbank_id": "https://go.drugbank.com/drugs/DB11075"
        },
        {
            "name": "POLYETHYLENE GLYCOL 400",
            "code": "B697894SGQ",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_13643"
        },
        {
            "name": "POLYSORBATE 80",
            "code": "6OZP39ZG8H",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_53426"
        },
        {
            "name": "D&C YELLOW NO. 10",
            "code": "35SW5USQ3G"
        },
        {
            "name": "FD&C BLUE NO. 2",
            "code": "L06K8R7DQK"
        },
        {
            "name": "SERTRALINE HYDROCHLORIDE",
            "code": "UTI8907Y6X",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_9124"
        }
    ],
    "indications": {
        "text": "sertraline tablets indicated treatment following [ ( 14 ) ] : major depressive disorder ( mdd ) obsessive-compulsive disorder ( ocd ) panic disorder ( pd ) posttraumatic stress disorder ( ptsd ) social anxiety disorder ( sad ) premenstrual dysphoric disorder ( pmdd )",
        "doid_entities": [
            {
                "text": "major depressive disorder (DOID:1470)",
                "doid_id": "http://purl.obolibrary.org/obo/DOID_1470"
            },
            {
                "text": "depressive disorder (DOID:1596)",
                "doid_id": "http://purl.obolibrary.org/obo/DOID_1596"
            },
            {
                "text": "obsessive-compulsive disorder (DOID:10933)",
                "doid_id": "http://purl.obolibrary.org/obo/DOID_10933"
            },
            {
                "text": "ocd (DOID:84)",
                "doid_id": "http://purl.obolibrary.org/obo/DOID_84"
            },
            {
                "text": "panic disorder (DOID:594)",
                "doid_id": "http://purl.obolibrary.org/obo/DOID_594"
            },
            {
                "text": "ptsd (DOID:2055)",
                "doid_id": "http://purl.obolibrary.org/obo/DOID_2055"
            },
            {
                "text": "anxiety (DOID:2030)",
                "doid_id": "http://purl.obolibrary.org/obo/DOID_2030"
            }
        ],
        "orphanet_entities": [
            {
                "disease": "obsessive-compulsive disorder",
                "orphanet_id": "http://www.orpha.net/ORDO/Orphanet_C052"
            }
        ]
    },
    "contraindications": {
        "text": "\u00adindication starting maximum mdd ( 2.1 ) 50 mg per day 200 mg per day ocd ( 2.1 ) 25 mg per day ( ages 6-12 ) 50 mg per day ( ages \u2265 13 ) 200 mg per day pd , ptsd , sad ( 2.1 ) 25 mg per day 200 mg per day pmdd ( 2.2 ) continuous dosing 50 mg per day 150 mg per day pmdd ( 2.2 ) intermittent dosing 50 mg per day luteal phase 100 mg per day luteal phase inadequate response starting , titrate 25-50 mg per day increments weekly mdd , ocd , pd , ptsd , sad ( 2.1 ) full prescribing information titration pmdd ( 2.2 ) hepatic impairment : mild : recommended starting maximum half recommended ( 2.4 ) moderate severe : recommended ( 2.4 ) discontinuing sertraline , reduce dose gradually ( 2.6 , 5.4 )",
        "doid_entities": [
            {
                "text": "ocd (DOID:84)",
                "doid_id": "http://purl.obolibrary.org/obo/DOID_84"
            },
            {
                "text": "ptsd (DOID:2055)",
                "doid_id": "http://purl.obolibrary.org/obo/DOID_2055"
            }
        ],
        "orphanet_entities": []
    },
    "warningsAndPrecautions": "sertraline 25 mg tablets : light green film coated modified oval biconvex tablets debossed left side bisect g right side bisect one side \u201c 212 \u201d ndc : 70518-4307-00 ndc : 70518-4307-01 packaging : 30 1 blister pack packaging : 90 1 bottle plastic store 20\u00b0c 25\u00b0c ( 68\u00b0f 77\u00b0f ) [ usp controlled room temperature ] . repackaged distributed : remedy repack , inc. 625 kolter dr. suite # 4 indiana , pa 1-724-465-8762",
    "adverseReactions": "sertraline contraindicated patients : taking , within 14 days stopping , maois , ( including maois linezolid intravenous methylene blue ) increased risk serotonin syndrome [ ( 5.2 ) , ( 7.1 ) ] . taking pimozide [ ( 7.1 ) ] . known hypersensitivity sertraline ( e.g . , anaphylaxis , angioedema ) [ ( 6.1 , 6.2 ) ] .",
    "indications_original": "Sertraline tablets are indicated for the treatment of the following\n \n  [See\n  \n   Clinical Studies (14)]\n \n  :\n\n \n                  \n                     Major depressive disorder (MDD)\n                     Obsessive-compulsive disorder (OCD)\n                     Panic disorder (PD)\n                     Posttraumatic stress disorder (PTSD)\n                     Social anxiety disorder (SAD)\n                     Premenstrual dysphoric disorder (PMDD)",
    "contraindications_original": "\u00adIndication Starting Dosage Maximum Dosage MDD (2.1) 50 mg per day 200 mg per day OCD (2.1) 25 mg per day (ages 6-12) 50 mg per day (ages \u2265 13) 200 mg per day PD, PTSD, SAD (2.1) 25 mg per day 200 mg per day PMDD (2.2) continuous dosing 50 mg per day 150 mg per day PMDD (2.2) intermittent dosing 50 mg per day during luteal phase only 100 mg per day during luteal phase only If inadequate response to starting dosage, titrate in 25-50 mg per day increments once weekly in MDD, OCD, PD, PTSD, and SAD ( 2.1 ) See Full Prescribing Information for titration in PMDD ( 2.2 ) Hepatic impairment: Mild: Recommended starting and maximum dosage is half recommended dosage ( 2.4 ) Moderate or severe: Not recommended ( 2.4 ) When discontinuing sertraline, reduce dose gradually ( 2.6 , 5.4 )",
    "warningsAndPrecautions_original": "Sertraline 25 mg Tablets: Light Green film coated Modified oval biconvex tablets debossed with I on the left Side of bisect and G on the right Side of bisect on one Side and \u201c212\u201d on other\n                  \n                  \n                  NDC: 70518-4307-00\n                  NDC: 70518-4307-01\n                  PACKAGING: 30 in 1 BLISTER PACK\n                  PACKAGING: 90 in 1 BOTTLE PLASTIC \n                  \n                  \n                  Store at 20\u00b0C to 25\u00b0C (68\u00b0F to 77\u00b0F) [see USP Controlled Room Temperature].\n                  \n                  \n                  Repackaged and Distributed By:\n                  Remedy Repack, Inc.\n                  625 Kolter Dr. Suite #4 Indiana, PA 1-724-465-8762",
    "adverseReactions_original": "Sertraline is contraindicated in patients:\n                  \n                     Taking, or within 14 days of stopping, MAOIs, (including the MAOIs linezolid and intravenous methylene blue) because of an increased risk of serotonin syndrome\n  \n   [See\n   \n    Warnings and Precautions (5.2),\n   \n    Drug Interactions (7.1)]\n  \n   .\n \n  \n                     Taking pimozide\n  \n   [\n   \n    See Drug Interactions (7.1)]\n  \n   .\n \n  \n                     With known hypersensitivity to sertraline (e.g., anaphylaxis, angioedema)\n  \n   [See\n   \n    Adverse Reactions (6.1,\n   \n    6.2)].",
    "drug": [
        {
            "name": "Sertraline Hydrochloride",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_9124"
        }
    ]
}